Alector Inc (NASDAQ:ALEC) — Market Cap & Net Worth
Market Cap & Net Worth: Alector Inc (ALEC)
Alector Inc (NASDAQ:ALEC) has a market capitalization of $166.65 Million ($166.65 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17186 globally and #4024 in its home market, demonstrating a 1.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alector Inc's stock price $1.51 by its total outstanding shares 110362581 (110.36 Million). See Alector Inc capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Alector Inc Market Cap History: 2019 to 2026
Alector Inc's market capitalization history from 2019 to 2026. Data shows change from $1.90 Billion to $166.65 Million (-28.24% CAGR).
Index Memberships
Alector Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.01% | #471 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1689 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.01% | #230 of 263 |
Weight: Alector Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alector Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alector Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.18x
Alector Inc's market cap is 8.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.90 Billion | $21.22 Million | -$99.81 Million | 89.62x | N/A |
| 2020 | $1.67 Billion | $21.10 Million | -$182.96 Million | 79.14x | N/A |
| 2021 | $2.28 Billion | $207.09 Million | -$28.01 Million | 11.01x | N/A |
| 2022 | $1.02 Billion | $133.62 Million | -$133.31 Million | 7.62x | N/A |
| 2023 | $880.69 Million | $97.06 Million | -$130.39 Million | 9.07x | N/A |
| 2024 | $208.59 Million | $100.56 Million | -$119.05 Million | 2.07x | N/A |
| 2025 | $172.17 Million | $21.05 Million | -$142.93 Million | 8.18x | N/A |
Competitor Companies of ALEC by Market Capitalization
Companies near Alector Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Alector Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Alector Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Alector Inc's market cap moved from $1.90 Billion to $ 166.65 Million, with a yearly change of -28.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $166.65 Million | -3.21% |
| 2025 | $172.17 Million | -17.46% |
| 2024 | $208.59 Million | -76.32% |
| 2023 | $880.69 Million | -13.54% |
| 2022 | $1.02 Billion | -55.30% |
| 2021 | $2.28 Billion | +36.48% |
| 2020 | $1.67 Billion | -12.19% |
| 2019 | $1.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Alector Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $166.65 Million USD |
| MoneyControl | $166.65 Million USD |
| MarketWatch | $166.65 Million USD |
| marketcap.company | $166.65 Million USD |
| Reuters | $166.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more